FNTA

Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha · P49354 · FNTA on Sugi Atlas →

104,339 patent compounds predicted against FNTA, 60,043 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Lonafarnib (SCHEMBL19032)	1.00	20/20
Lonafarnib (SCHEMBL94653)	1.00	20/20
Bms-214662 (SCHEMBL94663)	1.00	20/20
Bms-214662 (SCHEMBL134853)	0.74	20/20
Bms-214662 (SCHEMBL134854)	0.74	20/20
SCHEMBL153998	0.72	18/20
SCHEMBL152949	0.69	18/20
Farnesyl Diphosphate (SCHEMBL109441)	1.00	17/20
SCHEMBL155328	1.00	17/20
SCHEMBL155330	1.00	17/20
Farnesyl Diphosphate (SCHEMBL157143)	1.00	17/20
Farnesyl Diphosphate (SCHEMBL153997)	0.72	17/20
Geranyl Diphosphate (SCHEMBL109367)	0.97	16/20
Geranyl Diphosphate (SCHEMBL109368)	0.97	16/20
Geranyl Diphosphate (SCHEMBL152948)	0.94	16/20
Dimethylallyl Diphosphate (SCHEMBL153577)	0.70	16/20
Dimethylallyl Diphosphate (SCHEMBL156447)	0.70	16/20
SCHEMBL153576	0.43	16/20
Tipifarnib (SCHEMBL8097)	0.80	15/20
Tipifarnib (SCHEMBL94807)	0.80	15/20

Clinical trials — most relevant to FNTA by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in Subjects With Primary Hypercholesterolemia	PHASE3	COMPLETED
Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in Subjects With Primary Dyslipidemia	PHASE3	COMPLETED
Efficacy of Lapaquistat Acetate and Simvastatin in Subjects With Primary Dyslipidemia.	PHASE3	COMPLETED
NEO100 and High-Grade Meningioma	PHASE2	RECRUITING
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma	PHASE1/PHASE2	RECRUITING
Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC)	PHASE2	COMPLETED
Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria	PHASE2	COMPLETED
Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC	PHASE2	COMPLETED
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer	PHASE2	COMPLETED
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC	PHASE2	COMPLETED
Simvastatin in Secondary Progressive Multiple Sclerosis	PHASE2	COMPLETED
R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer	PHASE2	COMPLETED
A Phase 2 Study of Farnesyl Transferase Inhibitor (R115777, Tipifarnib) in Patients With Refractory or Relapsed Acute Myeloid Leukemia.	PHASE2	COMPLETED
Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels	PHASE2	COMPLETED
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis	PHASE2	UNKNOWN
Fosmidomycin With Clindamycin or With Clindamycin Plus Artesunate	PHASE2	WITHDRAWN
Fosmidomycin and Azithromycin for Acute Uncomplicated Plasmodium Falciparum Malaria (P. Malaria) in Adults	PHASE2	UNKNOWN
Clinical Effects of New Approach on Patients With Non-alcoholic Steatohepatitis	EARLY_PHASE1	COMPLETED
Statin Therapy and COVID-19 Infection	nan	COMPLETED
Statins and the Urinary Proteome	nan	COMPLETED
Epidemiology of Atherosclerosis	nan	COMPLETED
Use of Blood Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma (HCC)	nan	UNKNOWN
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity.	nan	COMPLETED
Mechanisms of Glucose Lowering Effect of Colesevelam HCl	nan	COMPLETED
Statin Therapy Versus Placebo Prior to Prostatectomy	nan	COMPLETED
Effect of Atorvastatin on 5-Fluorouracil Induced Mucositis	nan	UNKNOWN
A Registration Study for Familial Hypercholesterolemia in Taiwan	nan	UNKNOWN
A Study on Risk Mutations of Vulnerability Genes of Schizophrenia	nan	UNKNOWN
Ekvasis of Atorvastatin (Antorcin®) Treatment in Patients With Acute Cardiovascular Events	nan	COMPLETED
De Novo Lipogenesis in Severity of NAFLD	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a FNTA binder may also engage these)

Protein	Name	Similarity
Q61239	—	0.997	Q61239 →
P29702	—	0.997	P29702 →
Q04631	—	0.995	Q04631 →
Q9CZW5	—	0.955	Q9CZW5 →
Q75Q39	—	0.952	Q75Q39 →
Q96JC1	—	0.951	Q96JC1 →
Q5ZIA0	—	0.951	Q5ZIA0 →
Q6DC64	—	0.949	Q6DC64 →
PTAR1	Protein prenyltransferase alpha subunit repeat-containing protein 1	0.948	landscape →
Q923S8	—	0.948	Q923S8 →
HELZ	Probable helicase with zinc finger domain	0.948	landscape →
Q8VE62	—	0.946	Q8VE62 →
F1N9S8	—	0.945	F1N9S8 →
Q80UY1	—	0.945	Q80UY1 →
Q6DFV5	—	0.945	Q6DFV5 →
P11029	—	0.945	P11029 →
Q9P260	—	0.944	Q9P260 →
Q5R5F8	—	0.944	Q5R5F8 →
Q8N4J0	—	0.944	Q8N4J0 →
METTL16	RNA N(6)-adenosine-methyltransferase METTL16	0.944	landscape →
Q8C1Z7	—	0.943	Q8C1Z7 →
Q9NVE7	—	0.943	Q9NVE7 →
E1C1R4	—	0.943	E1C1R4 →
ACACA	Acetyl-CoA carboxylase 1	0.943	landscape →
Q4R4U1	—	0.942	Q4R4U1 →
Q148V7	—	0.942	Q148V7 →
Q8L5Y9	—	0.942	Q8L5Y9 →
Q9CQG2	—	0.942	Q9CQG2 →
P11497	—	0.942	P11497 →
Q96RK4	—	0.942	Q96RK4 →